CureVac NV
CVAC5.350USD
-0.010-0.19%
收盤 09/18, 16:00（美東）報價延遲15分鐘
1.20B總市值
6.22本益比TTM
關於 CureVac NV 公司
CureVac NV（前身爲 CureVac AG）是一家總部位於德國的臨牀階段生物製藥公司。該公司開發基於信使核糖核酸 (mRNA) 的轉化藥物。該公司的 mRNA 旨在通過模仿人類生物學合成所需蛋白質來預防感染和治療疾病。其技術平臺優化了編碼功能性蛋白質的 mRNA 構建體，這些蛋白質要麼誘導所需的免疫反應，要麼使用細胞固有的翻譯機制替換有缺陷或缺失的蛋白質。該公司的產品組合包括預防性疫苗、腫瘤學和分子治療等多種疾病適應症的臨牀和臨牀前候選藥物。在預防性疫苗方面，該公司正在與葛蘭素史克 (GSK) 合作，推進其針對嚴重急性呼吸道綜合徵冠狀病毒 2 (SARS-CoV-2) 和一系列傳染病（包括季節性流感）的第二代 mRNA 骨架。
公司簡介
公司代碼CVAC
公司名稱CureVac NV
上市日期Aug 14, 2020
CEODr. Alexander Zehnder, M.D.
員工數量825
證券類型Ordinary Share
年結日Aug 14
公司地址Friedrich-Miescher-Str. 15
城市TUEBINGEN
上市交易所NASDAQ Global Market Consolidated
國家Germany
郵編72076
電話49707198830
網址https://www.curevac.com/
公司代碼CVAC
上市日期Aug 14, 2020
CEODr. Alexander Zehnder, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
收入明細
單位: EUR更新時間: 7月6日 週日
單位: EUR更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
暫無數據
地區EUR
名稱
營收
佔比
Switzerland
586.00K
65.62%
Belgium (Country)
306.00K
34.27%
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
其他
42.80%
持股股東
持股股東
佔比
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
其他
42.80%
股東類型
持股股東
佔比
Corporation
36.61%
Government Agency
13.27%
Holding Company
7.37%
Hedge Fund
2.00%
Investment Advisor/Hedge Fund
1.68%
Investment Advisor
1.14%
Foundation
0.70%
Research Firm
0.63%
Bank and Trust
0.25%
其他
36.36%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
250
140.06M
62.20%
-14.31M
2025Q1
256
140.77M
62.52%
-15.67M
2024Q4
257
142.22M
63.40%
-15.15M
2024Q3
264
144.04M
64.21%
-15.50M
2024Q2
284
147.06M
65.56%
-13.88M
2024Q1
303
150.44M
67.06%
-10.89M
2023Q4
317
154.94M
69.64%
-16.33M
2023Q3
339
166.99M
75.03%
-5.02M
2023Q2
359
168.77M
75.83%
-4.22M
2023Q1
383
169.76M
76.27%
+21.54M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
DH Capital GmbH & Co. KG
70.18M
31.17%
--
--
Jun 12, 2025
KfW
29.87M
13.27%
--
--
Mar 15, 2025
Glaxo Group, Ltd.
16.59M
7.37%
--
--
Mar 15, 2025
DH-LT-Investments GmbH
8.75M
3.89%
--
--
Jun 12, 2025
Zweite DH Verwaltungs GmbH
3.40M
1.51%
--
--
Jun 12, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
查看更多
持股ETF
更新時間: 9月2日 週二
更新時間: 9月2日 週二
機構名稱
佔比
AltShares Merger Arbitrage ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Global X Genomics & Biotechnology ETF
0.62%
WisdomTree BioRevolution Fund
0.59%
NYLI Merger Arbitrage ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.12%
iShares Biotechnology ETF
0.05%
iShares MSCI Europe Small-Cap ETF
0.05%
iShares MSCI EAFE Small-Cap ETF
0.02%
查看更多
AltShares Merger Arbitrage ETF
佔比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.14%
Global X Genomics & Biotechnology ETF
佔比0.62%
WisdomTree BioRevolution Fund
佔比0.59%
NYLI Merger Arbitrage ETF
佔比0.38%
ProShares Ultra Nasdaq Biotechnology
佔比0.13%
Invesco Nasdaq Biotechnology ETF
佔比0.12%
iShares Biotechnology ETF
佔比0.05%
iShares MSCI Europe Small-Cap ETF
佔比0.05%
iShares MSCI EAFE Small-Cap ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
